Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.
Genmab A/S announced that the first participants have been dosed in a clinical study of a DuoBody bispecific antibody under Genmab’s DuoBody technology platform collaboration with Janssen Biotech, Inc. (Janssen). The phase I study investigates the human bispecific antibody JNJ-61178104, which is directed to two inflammatory disease targets, for potential use in treating autoimmune disorders. Genmab will receive a $2 million milestone payment for the progress in the study.
Neurotrope, Inc., a clinical-stage company developing a disruptive therapy for the treatment of severe Alzheimer's disease (AD), has entered into a research collaboration with the International Rett Syndrome Foundation, DBA: Rettsyndrome.org, to explore the potential of Bryostatin for the treatment of Rett syndrome.
[adsense:336x280:8701650588]
Boston Scientific Corporation announced the introduction of the Precision Montage MRI Spinal Cord Stimulator (SCS) System after receiving approval from the US Food and Drug Administration.
Entresto® (sacubitril/valsartan) has been given a Class I recommendation, the strongest endorsement, in updated clinical practice guidelines simultaneously released by the American College of Cardiology (ACC), the American Heart Association (AHA) and the Heart Failure Society of America (HFSA) in the US, and the European Society of Cardiology in the EU.
In the US Entresto is now a standard therapy for heart failure with reduced ejection fraction (HFrEF) as an alternative to an ACE inhibitor or an angiotensin II receptor blocker, given together with a beta blocker and an aldosterone antagonist. In addition, the guidelines call for doctors to switch HFrEF patients with mild to moderate symptoms from ACEs or ARBs to Entresto.
"These strong, swift and broad recommendations by US cardiology organizations, redefine the standard of care for how reduced ejection fraction heart failure is treated," said Vas Narasimhan, Global Head of Development and Chief Medical Officer for Novartis. "We know patients with heart failure suffer reduced quality of life and remain at high risk of hospitalization or death, and these new guidelines are a strong call to action to ensure patients receive the most effective therapies."
In the EU, the ESC HF guidelines recommend doctors switch HFrEF patients meeting the PARADIGM-HF criteria to Entresto from an ACE or ARB. Both guideline committees considered evidence from PARADIGM-HF, the largest heart failure trial ever, which showed Entresto significantly reduced deaths from cardiovascular causes and heart failure hospitalizations in patients with HFrEF.
Waters has now unveiled the new Xevo TQ-XS mass spectrometer, which is far advanced sensitive bench-top tandem quadrupole instrument. It features a unique combination of ion optics, detection and ionization technologies resulting in levels of sensitivity not previously seen. The Xevo TQ-XS is expected to be available for shipment in June 2016 and was on public display for the first time at MSSJ in Osaka, Japan, May 18 – 20. It will be on display at ASMS in San Antonio, TX, June 5 – 9.
Pfizer Inc. (NYSE:PFE) and Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Anacor for $99.25 per Anacor share, in cash, for a total transaction value, net of cash, of approximately $5.2 billion, which assumes the conversion of Anacor’s outstanding convertible notes. The Boards of Directors of both companies have unanimously approved the transaction. Anacor’s flagship asset, crisaborole, a differentiated non-steroidal topical PDE4 inhibitor with anti-inflammatory properties, is currently under review by the U.S. FDA for the treatment of mild-to-moderate atopic dermatitis, commonly referred to as eczema.
Combining radiation treatments with a new generation of immunotherapies is showing promise as a one-two-punch against melanoma, Loyola Medicine researchers report in the Journal of Radiation Oncology.Radiation kills cancer cells by damaging their DNA. Immunotherapies work by harnessing a patient's immune system to attack and kill cancer cells. When combined, the two therapies appear to have synergistic effects, according to the article by James S. Welsh, MD and colleagues.
A type of brain cell known as microglia plays a key role in reducing the effects of cocaine in the brain, according to a major study by a team from the Research Institute of the McGill University Health Centre (RI-MUHC) in Montreal.
Using gene editing technology, researchers at the Lewis Katz School of Medicine at Temple University have, for the first time, successfully excised a segment of HIV-1 DNA - the virus responsible for AIDS - from the genomes of living animals. The breakthrough, described online this month in the journal Gene Therapy, is a critical step in the development of a potentially curative strategy for HIV infection.
The discovery of penicillin has led to a sharp decline of syphilis around the world, except in Africa. In a new study, Prof. Chris Kenyon of the Antwerp Institute of Tropical Medicine (ITM) describes the different rates of decline of syphilis around the world. This week the European Centre of Disease Prevention and Control (ECDC) also published its latest figures on syphilis in Europe.
CLICK HERE TO SUBSCRIBE,
PHARMATUTOR's DAILY EMAILS
Do Not Forget to Verify
(Click on Subscription link in your inbox)
--------
